Literature DB >> 18040647

Effects on kidney disease, fertility and development in mice inheriting a protein-truncating Denys-Drash syndrome allele (Wt1tmT396).

Charles E Patek1, David G Brownstein, Stewart Fleming, Caroline Wroe, Lorraine Rose, Anna Webb, Rachel L Berry, Paul S Devenney, Marion Walker, Oliver D K Maddocks, Nicola J Lawrence, David J Harrison, Katrina M Wood, Colin G Miles, Martin L Hooper.   

Abstract

Denys-Drash syndrome (DDS) is caused by heterozygous mutations of the Wilms' tumour suppressor gene, WT1, characterised by early-onset diffuse mesangial sclerosis often associated with male pseudohermaphroditism and/or Wilms' tumourigenesis. Previously, we reported that the Wt1tmT396 allele induces DDS kidney disease in mice. In the present study heterozygotes (Wt1tmT396/+) were generated on inbred (129/Ola), crossbred (B6/129) and MF1 second backcross (MF1-N2) backgrounds. Whereas male heterozygotes on each background were fertile, inbred heterozygous females were infertile. Kidney disease (proteinuria and sclerosis) was not congenital and developed significantly earlier in inbred mice, although with variable onset. Disease onset in MF1-N2 stocks occurred later in Wt1tmT396/+ mice than reported previously for Wt1R394W/+ mice, and while no kidney disease has been reported in B6/129 Wt1+/- mice, B6/129 Wt1tmT396/+ mice were affected. Offspring of both male and female B6/129 and MF1-N2 Wt1tmT396/+ mice developed kidney disease, but its incidence was significantly higher in offspring of female heterozygotes. Wt1tmT396/tmT396 embryos exhibited identical developmental abnormalities to those reported for Wt1-/- embryos. The results indicate that the Wt1 (tmT396) allele does not predispose to Wilms' tumourigenesis or male pseudohermaphroditism, its effect on kidney disease and female fertility depends on genetic background, stochastic factors may affect disease onset, and disease transmission is subject to a partial parent-of-origin effect. Since the Wt1tmT396 allele has no detectable intrinsic functional activity in vivo, and kidney disease progression is affected by the type of Wt1 mutation, the data support the view that DDS nephropathy results from a dominant-negative action rather than WT1 haploinsufficiency or gain-of-function.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18040647     DOI: 10.1007/s11248-007-9157-0

Source DB:  PubMed          Journal:  Transgenic Res        ISSN: 0962-8819            Impact factor:   2.788


  56 in total

1.  Clinical spectrum of Denys-Drash and Frasier syndrome.

Authors:  S J McTaggart; E Algar; C W Chow; H R Powell; C L Jones
Journal:  Pediatr Nephrol       Date:  2001-04       Impact factor: 3.714

2.  Spectrum of early onset nephrotic syndrome associated with WT1 missense mutations.

Authors:  V Schumacher; K Schärer; E Wühl; H Altrogge; K E Bonzel; M Guschmann; T J Neuhaus; R M Pollastro; E Kuwertz-Bröking; M Bulla; A M Tondera; P Mundel; U Helmchen; R Waldherr; A Weirich; B Royer-Pokora
Journal:  Kidney Int       Date:  1998-06       Impact factor: 10.612

3.  Wilms' tumor 1 and Dax-1 modulate the orphan nuclear receptor SF-1 in sex-specific gene expression.

Authors:  M W Nachtigal; Y Hirokawa; D L Enyeart-VanHouten; J N Flanagan; G D Hammer; H A Ingraham
Journal:  Cell       Date:  1998-05-01       Impact factor: 41.582

4.  WT-1 is required for early kidney development.

Authors:  J A Kreidberg; H Sariola; J M Loring; M Maeda; J Pelletier; D Housman; R Jaenisch
Journal:  Cell       Date:  1993-08-27       Impact factor: 41.582

5.  Two N-terminal self-association domains are required for the dominant negative transcriptional activity of WT1 Denys-Drash mutant proteins.

Authors:  G Holmes; S Boterashvili; M English; B Wainwright; J Licht; M Little
Journal:  Biochem Biophys Res Commun       Date:  1997-04-28       Impact factor: 3.575

6.  The Wilms tumor suppressor gene wt1 is required for development of the spleen.

Authors:  U Herzer; A Crocoll; D Barton; N Howells; C Englert
Journal:  Curr Biol       Date:  1999 Jul 29-Aug 12       Impact factor: 10.834

Review 7.  A review of the phenotypic variation due to the Denys-Drash syndrome-associated germline WT1 mutation R362X.

Authors:  Rosemary W Heathcott; Ian M Morison; Marie Claire Gubler; Robin Corbett; Anthony E Reeve
Journal:  Hum Mutat       Date:  2002-04       Impact factor: 4.878

8.  Different isoforms of the Wilms' tumour protein WT1 have distinct patterns of distribution and trafficking within the nucleus.

Authors:  J R Dutton; D Lahiri; A Ward
Journal:  Cell Prolif       Date:  2006-12       Impact factor: 6.831

Review 9.  The many facets of the Wilms' tumour gene, WT1.

Authors:  Peter Hohenstein; Nicholas D Hastie
Journal:  Hum Mol Genet       Date:  2006-10-15       Impact factor: 6.150

10.  Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing.

Authors:  S H Larsson; J P Charlieu; K Miyagawa; D Engelkamp; M Rassoulzadegan; A Ross; F Cuzin; V van Heyningen; N D Hastie
Journal:  Cell       Date:  1995-05-05       Impact factor: 41.582

View more
  4 in total

Review 1.  The influence of genetics in congenital diaphragmatic hernia.

Authors:  Lan Yu; Rebecca R Hernan; Julia Wynn; Wendy K Chung
Journal:  Semin Perinatol       Date:  2019-08-01       Impact factor: 3.300

Review 2.  Genetically Modified Mouse Models of Congenital Diaphragmatic Hernia: Opportunities and Limitations for Studying Altered Lung Development.

Authors:  Florian Friedmacher; Udo Rolle; Prem Puri
Journal:  Front Pediatr       Date:  2022-05-13       Impact factor: 3.569

Review 3.  Wt1 in the kidney--a tale in mouse models.

Authors:  Derya Deniz Ozdemir; Peter Hohenstein
Journal:  Pediatr Nephrol       Date:  2013-11-18       Impact factor: 3.714

4.  Whole exome sequencing identified a rare WT1 loss-of-function variant in a non-syndromic POI patient.

Authors:  Yingchen Wang; Qing Chen; Feng Zhang; Xi Yang; Lingyue Shang; Shuting Ren; Yuncheng Pan; Zixue Zhou; Guoqing Li; Yunzheng Fang; Li Jin; Yanhua Wu; Xiaojin Zhang
Journal:  Mol Genet Genomic Med       Date:  2021-11-29       Impact factor: 2.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.